⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IKT News
Inhibikase Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
IKT
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
globenewswire.com
IKT
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
globenewswire.com
IKT
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
IKT
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
globenewswire.com
IKT
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
globenewswire.com
IKT
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
globenewswire.com
IKT